Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.
- Conditions
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00493532
BONDIR Study: A Study of Intravenous Bonviva (Ibandronate) After Recent Vertebral Osteoporotic Fracture in Patients With Osteoporosis.
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2016-03-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 68
- Registration Number
- NCT00493623
A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors.
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT00493155
A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients
Phase 4
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-06-19
- Last Posted Date
- 2011-07-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 29
- Registration Number
- NCT00488059
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
- First Posted Date
- 2007-06-19
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT00487747
A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-06-15
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 47
- Registration Number
- NCT00487188
A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-06-15
- Last Posted Date
- 2017-07-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 787
- Registration Number
- NCT00486759
- Locations
- 🇫🇷
Hopital Saint Jean; Hematologie, Perpignan, France
🇺🇸Uni of California - San Diego; Cancer Center & Dept of Medicine, La Jolla, California, United States
🇺🇸Kenmar Research Inst., Whittier, California, United States
A Study of Bevacizumab (Avastin) in Combination With Capecitabine (Xeloda) in Elderly Patients With Metastatic Colorectal Cancer
- First Posted Date
- 2007-06-12
- Last Posted Date
- 2015-01-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 280
- Registration Number
- NCT00484939
The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-06-08
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 236
- Registration Number
- NCT00483938
A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease.
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2007-05-24
- Last Posted Date
- 2017-08-16
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00478270
© Copyright 2024. All Rights Reserved by MedPath